Free cash flow remains consistently negative, with outflows reaching $1.8 million in 2026Q1, indicating that the company's $5.6 million cash position is rapidly depleting.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) cash flow statement — 5-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Cash from Operations | -4.91M | -3.69M | -5.07M | -3.86M | -468.66K | -119.4K |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | -241.64% | 27.26% | -31.37% | -723.58% | -292.53% | - |
| Net Income | -5.88M | -10.41M | -16.53M | -13.07M | -854.15K | -138.13K |
| Depreciation & Amortization | 0 | 0 | 4.34M | 0 | 0 | 0 |
| Stock-Based Compensation | -503.32K | 5.29M | 6.87M | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.42M | 840K | 130K | 9.1M | 0 | 0 |
| Working Capital Changes | 45.04K | 594.69K | 126.47K | 113.84K | 385.49K | 18.73K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -133.85K | -50.77K | 183.63K | 114.56K | 0 | 0 |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 9.33M | 9.71M | 6.34M | 3.86M | 470.08K | 119.4K |
| Debt Issued (Net) | 0 | 0 | -101K | 3.17M | 462.39K | 0 |
| Equity Issued (Net) | 9.51M | 9.55M | 6.83M | 1M | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -181.34K | 155.52K | -396.64K | -310.38K | 7.69K | 119.4K |
| Net Change in Cash | 4.42M | 6.02M | 1.26M | -188 | 1.42K | 0 |
| Free Cash Flow | -4.91M | -3.69M | -5.07M | -3.86M | -468.66K | -119.4K |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | -55.14% | 27.26% | -31.36% | -723.58% | -292.53% | - |
| FCF per Share | -0.14 | -0.12 | -0.17 | -0.13 | -0.02 | -0.00 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.35x | 0.31x | 0.30x | 0.55x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying TELO stock.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) generated $-3.7M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported negative free cash flow of $3.7M in 2025, indicating capital requirements exceeded cash from operations.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Binary clinical trial failure
Metrics are mathematically derived from official filings.
Earnings Disconnect Masks Cash Burn
As reported in financial statements, TELO's OCF/NI ratio has fluctuated wildly, ranging from 0.12 to 1.79, which suggests that net income is a poor proxy for the company's actual cash requirements as it navigates the pre-clinical development phase without any meaningful revenue generation to stabilize operations.
The significant divergence between net losses and operating cash flow indicates that non-cash items and working capital adjustments are creating noise in the financial reporting. Investors should monitor this volatility, as it obscures the true underlying cash burn rate required to sustain the company's research activities.
Persistent Negative Free Cash Flow
Based on the provided quarterly data, TELO has consistently reported negative free cash flow, with outflows reaching $1.9M in 2024Q1, confirming that the company remains in a capital-intensive phase where cash consumption is entirely decoupled from any form of commercial or operational self-sufficiency.
The lack of positive free cash flow is expected for a pre-clinical entity, yet the trend shows no signs of stabilization. This trajectory suggests that the company will remain dependent on external financing until a major value-inflection point is reached, which may be further away than the current cash balance implies.
Working Capital Volatility Impacts Liquidity
According to recent SEC filings, TELO's working capital changes have been erratic, swinging from a $867.8K inflow in 2025Q4 to an $822.4K outflow in 2026Q1, which indicates that the company's short-term liquidity is highly sensitive to the timing of vendor payments and research-related accruals.
This instability in working capital management may reflect the company's struggle to manage cash outflows while scaling pre-clinical testing. Such fluctuations warrant further investigation, as they could exacerbate the company's already precarious cash position during periods of high research activity.
SBC Obscures True Cash Needs
As indicated by historical financial data, TELO utilized $8.3M in stock-based compensation during 2024 and 2025, a practice that effectively masks the true economic cost of talent retention and defers the immediate cash impact of operating expenses at the expense of future shareholder dilution.
While stock-based compensation preserves current cash, it represents a significant future claim on equity that is not captured in the headline cash burn figures. Analysts should adjust their models to account for this dilution, as it suggests that the company's reliance on equity to fund operations is structurally embedded.